A Study of Setmelanotide in Patients With Prader-Willi Syndrome

NCT06772597 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Prader-Willi Syndrome
Obesity
Hyperphagia

Interventions

DRUG: Setmelanotide

Sponsor

Rhythm Pharmaceuticals, Inc.